MedTrace Logo

Radium 223 Following Intermittent ADT

NCT02656563 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-10-14

No results posted yet for this study

Summary

This is a multicentre, phase II, randomized, open label study to evaluate the efficacy and safety of monthly Radium 223 in prolonging the off treatment interval of men with localized prostate cancer receiving intermittent androgen ablation therapy for a rising PSA post-radiation or post-prostatectomy, who are at high risk for occult metastases.

Conditions

Interventions

RADIATION

Radium 223 Dichloride (Xofigo®)

Radium 223 Dichloride (Xofigo®) monthly for six months

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Canadian Urology Research Consortium

    lead OTHER

Principal Investigators

  • Laurence Klotz, MD · Canadian Urology Research Consortium

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2020-10-31
Completion
2020-10-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656563 on ClinicalTrials.gov